Hyderabad: Bharat Biotech has received permission for drug controllers from India (DCGI) to conduct clinical trials of phase-III from intranasal vaccine Covid-19 BBV154 as a booster for other vaccines.
The drug regulator is also studied to give its approval to the company to conduct phase-III trials to compare the immunogenicity and security of the nose vaccine with covaxin.
“BBV154 (Nasal Covid Vaccine) has received approval for phase clinical trials 3.
The trial will evaluate the nose vaccine for the 2-dose schedule and a booster dose schedule” Bharat Biotech on Friday.
The company said intranasal vaccines are easier to provide in mass immunization campaigns and can help reduce or stop SARS-COV-2 transmission.
While the test of the booster dose is scheduled to be carried out on five sites, the two main doses must be carried out at 9 centers, said the source.
Chancanzee Adenovirus vector vaccine is being developed by Bharat Biotech along with Washington University in St.
Louis.
The company has completed the intranasal vaccine trial where there are three cohorts.
Nasal bharat biotech booster gets a nod for trial
